Image
The poster child for drug company profiteering. 

People Before Pharma Profit

Gilead continues charging exorbitant prices for lifesaving HIV medication, putting enormous strain on the public programs people depend on for care. Biktarvy, the most prescribed HIV drug in America, carries an annual list price of more than $60,000 per patient. Even after discounts and rebates, the cost to public HIV programs remains dangerously high.

Gilead reported $29 billion in revenue last year. While the company thrives, HIV safety-net programs are being pushed closer to crisis.

Florida Is Paying the Price

This year, Florida cut 11,500 people living with HIV from ADAP coverage and removed Biktarvy from the formulary. People who had been stable, healthy, and virally suppressed because of this medication were suddenly told they could lose access.

More than 60% of Florida’s ADAP clients depend on Biktarvy. When one drug becomes this essential, Gilead’s greed puts lives, treatment continuity, and public health at risk.

Image
Image

Gilead Must Act Now

Gilead has the power to offer meaningful pricing relief to public HIV programs. It has refused. That refusal has consequences. When people lose access to treatment, they risk falling out of care, losing viral suppression, and facing worse health outcomes.

Gilead can afford to lower prices. Patients cannot afford this crisis.

#PutPeopleFirst

Gilead Sciences wants you to believe they are a benevolent organization working to help people. They say they have bold ambitions to create a healthier world for everyone. In reality, Gilead’s bold ambitions are more focused on creating wealth for their executives and shareholders. 

Price gouging, withholding of safer HIV medicines, and slashing patient assistance programs – this is the real Gilead. Gilead is making billions of dollars in profits off taxpayer-subsidized research for many of the prescription drugs they sell. Gilead doesn’t put people first – unless they are shareholders.

Image
Image
Image
Image
Gilead’s greed has no limit.
Gilead has made tens of billions of dollars from drug price gouging.
Gilead has opportunistically raised the price to safety net providers of their HIV drugs, creating higher costs for nonprofit HIV clinics all over the country. This has a direct negative impact on HIV care and treatment.
Gilead is being sued by thousands of HIV patients for knowingly selling an inferior drug.
Gilead will pay $246.75 million to customers who purchased the drugs Truvada or Atripla, or any of the two drugs’ generic versions, during a period of about five years. This is just one of many lawsuits attempting to hold Gilead accountable for its relentless greed.
Gilead has slashed its patient assistance program that supported HIV nonprofits.
Greedy Gilead subsidized non-profit community HIV service organizations to help offset their overhead costs. When Truvada went off-patent, they cynically withdrew the subsidies, causing many of them to drastically reduce services.
Gilead has doubled the price of their HIV prevention drug Descovy.
Greedy Gilead kept Descovy, an important HIV drug off the market, until the patent on its inferior Truvada drug expired, so it could squeeze more profit while putting the health of people living with HIV at risk.
Gilead has placed illegal restrictions on 340B access to increase their profits.
Gilead placed unlawful restrictions on 340B contract pharmacy programs, a move that greatly reduces the number of prescriptions that nonprofit safety net care providers can fill for patients and clients.
Gilead jeopardizes the ability of safety-net providers to provide services & help patients.
Gilead has unilaterally stopped giving safety net providers access to discounted drug prices for their patients who fill their prescriptions at their provider’s contracted pharmacy. This brazenly flouts federal law.
Gilead priced several HIV & hepatitis C drugs out of reach for people in developing countries.
Gilead refuses to register some medications in developing countries, and consistently uses its patent monopolies to block attempts to introduce cheaper, generic versions of its medicines.

It’s Time to Put an End To Corporate Greed

AIDS Advocates Lead the Way

AIDS Healthcare Foundation led a rally and protest at drug maker Gilead Sciences’ headquarters in Foster City, CA; Washington, DC; and Miami, FL. The protest targeted Gilead’s move to undermine safety net providers’ access to 340B drug pricing program benefits. Gilead now becomes the 15th drug company to illegally restrict access to certain drugs.
Image
Image
Thirty countries across Africa, the Americas, Asia, and Europe banded together in solidarity this past June by launching the "30 Days, 30 Countries" campaign – 30 consecutive days of advocacy against #GreedyGilead’s high drug prices, blocking access to generic medicines via its patent monopolies, and its overall shameful profiteering. Check out the video below of all the actions!
Click here to read more about all the advocacy actions that took place throughout 30 countries in June.

Gilead has priced several of its HIV and hepatitis C drugs out of reach for many people, refused to register some medications in developing countries, and consistently uses its patent monopolies to block attempts to introduce cheaper, generic versions of its medicines. 

AHF is taking its grassroots campaign global to raise awareness about Gilead’s shameful practices and calling on the company to do the following:

  • Stop evergreening patents on existing HIV/AIDS drugs like Truvada – this is exploitation, not innovation.
  • Open the license for the generic production of the hepatitis C drug Harvoni to all low- and middle-income countries, without exception.
  • For the duration of the COVID-19 pandemic, sell or license remdesivir for generic distribution at a nonprofit price.
  • License technology to produce cryptococcal meningitis to generic manufacturers.
  • Link executive compensation to the impact on positive public health outcomes and access to medicines in developing countries.

#GreedyGilead

Load More

AIDS Healthcare Foundation 2024

Contact Us

Questions? Comments? Send our team a message, and we’ll get back to you as soon as we can. Thank you for being an active participant in our fight against corporate greed.
Image

Navigation

Who Is Gilead?
Gilead's Greed Has No Limit
Get The Facts

Quick Links

News
Tweet #GreedyGilead
30 Days, 30 Countries

Resources